Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Van de Werf, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van de Werf, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


New aspects of pharmacological reperfusion: from macro- to microlysis

F. Van de Werf1

Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium

1 Correspondence: Frans Van de Werf, MD, Chairman, Department of Cardiology, U.Z. Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

Abstract

Recanalization of the occluded infarct-related coronary artery limits infarct size and reduces morbidity and mortality of patients with ST-segment elevation acute coronary syndromes. While of crucial prognostic significance, early patency of the infarct-related coronary artery does not tell the entire story: patency must be maintained to alter prognosis; patency of the epicardial infarct vessel does not equal re-establishment of myocardial tissue perfusion; and even late patency may be beneficial through other mechanisms that depend less on time and myocardial salvage, such as prevention of infarct expansion and left ventricular dilatation, and improvement of electrical stability. New promising strategies that may improve patency of both the epicardial coronary artery (macrolysis) and the distal vasculature (microlysis) are being evaluated. Of particular interest is the combined use of glycoprotein IIb/IIIa receptor antagonists and reduced dose fibrinolytics. This combination is currently being tested in three angiographic trials (FASTER, INTEGRITI, ENTIRE) and in two large trials with clinical end-points (GUSTO-V and ASSENT-3). Furthermore, new promising agents that can limit ischaemia reperfusion injury have entered the clinical testing phase. It is likely that these new strategies will further improve the efficacy of pharmacological reperfusion.

Key Words: pharmacological perfusion • microlysis • macrolysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.